Journal Menu
► ▼ Journal Menu-
- Marine Drugs Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal Browser-
arrow_forward_ios
Forthcoming issue
arrow_forward_ios Current issue - Vol. 22 (2024)
- Vol. 21 (2023)
- Vol. 20 (2022)
- Vol. 19 (2021)
- Vol. 18 (2020)
- Vol. 17 (2019)
- Vol. 16 (2018)
- Vol. 15 (2017)
- Vol. 14 (2016)
- Vol. 13 (2015)
- Vol. 12 (2014)
- Vol. 11 (2013)
- Vol. 10 (2012)
- Vol. 9 (2011)
- Vol. 8 (2010)
- Vol. 7 (2009)
- Vol. 6 (2008)
- Vol. 5 (2007)
- Vol. 4 (2006)
- Vol. 3 (2005)
- Vol. 2 (2004)
- Vol. 1 (2003)
Need Help?
Announcements
13 June 2023
Marine Drugs Receives an Increased CiteScore of 9.6
We are pleased to inform you that Marine Drugs (ISSN: 1660-3397) has received an updated CiteScore of 9.6, an increase of 18.5% compared with the 2021 metric. The 2022 CiteScore™ was released recently, making an assessment of the scientific influence of journals in the 2019 to 2022 period.
Marine Drugs’ CiteScore ranks as follows:
- Q1 (3 out of 32) in the "Pharmacology, Toxicology and Pharmaceutics (miscellaneous)" category;
- Q1 (23 out of 171) in the "Pharmaceutical Science" category;
- Q1 (24 out of 156) in the "Drug Discovery" category.
For more journal statistics, please visit https://www.mdpi.com/journal/marinedrugs/stats.
Excellent performance is inseparable from the support and dedication of all journal editors, reviewers, authors, and readers. We would like to take this opportunity to thank all of you who have contributed to the journal.
